Prescient Therapeutics (ASX: PTX) advances innovative cancer therapies following successful FY 2021 (w/ Steven Yatomi-Clarke)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company's innovative pipeline of personalised cancer therapies. The company is developing customised approaches to treating cancer including targeted and cellular therapies. Mr Yatomi-Clarke describes Prescient as a compelling investment case which is well-funded to deliver value-adding milestones across its various cancer treatments.